Lantheus/$LNTH
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Lantheus
Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.
Ticker
$LNTH
Sector
Health Care
Primary listing
Employees
808
Headquarters
Website
Lantheus Metrics
BasicAdvanced
$3.6B
13.75
$3.77
-
-
Price and volume
Market cap
$3.6B
52-week high
$115.01
52-week low
$47.25
Average daily volume
1.5M
Financial strength
Current ratio
4.29
Quick ratio
3.685
Long term debt to equity
57.339
Total debt to equity
57.408
Interest coverage (TTM)
22.00%
Profitability
EBITDA (TTM)
494.4
Gross margin (TTM)
63.75%
Net profit margin (TTM)
17.82%
Operating margin (TTM)
28.46%
Effective tax rate (TTM)
28.00%
Revenue per employee (TTM)
$1,880,000
Management effectiveness
Return on assets (TTM)
13.34%
Return on equity (TTM)
24.71%
Valuation
Price to earnings (TTM)
13.749
Price to revenue (TTM)
2.352
Price to book
3.05
Price to tangible book (TTM)
5.64
Growth
Revenue change (TTM)
5.75%
Earnings per share change (TTM)
-37.87%
3-year revenue growth (CAGR)
31.80%
10-year revenue growth (CAGR)
17.59%
3-year earnings per share growth (CAGR)
101.44%
10-year earnings per share growth (CAGR)
10.82%
What the Analysts think about Lantheus
Analyst ratings (Buy, Hold, Sell) for Lantheus stock.
Bulls say / Bears say
Lantheus' Alzheimer's disease radiodiagnostic, MK-6240, met co-primary endpoints in two pivotal studies, demonstrating strong sensitivity and specificity in detecting tau pathology, with plans to submit a New Drug Application to the FDA in Q3 2025. (stocktitan.net)
The acquisition of Life Molecular Imaging Ltd. for up to $750 million, including $350 million upfront, expands Lantheus' presence in Alzheimer's disease diagnostics with Neuraceq, an F-18 PET imaging agent for β-amyloid plaque detection. (benzinga.com)
Lantheus' proprietary imaging agent, PYLARIFY, achieved over $1 billion in annual sales, indicating strong market demand and contributing to a 10.5% year-on-year sales increase in Q4 2024. (financialcontent.com)
The potential patent expiration of PYLARIFY in 2026 poses a risk to Lantheus' revenue stream, as the company seeks to extend protections and diversify its offerings. (wallstrank.com)
Insider selling activity, including Director Mary Anne Heino's sale of 53,107 shares on March 3, 2025, may raise concerns about internal confidence in the company's future performance. (etfdailynews.com)
The $350 million acquisition of Life Molecular Imaging led to a 4.4% drop in Lantheus' stock price, indicating investor apprehension about the financial impact of the deal. (benzinga.com)
Data summarised monthly by Lightyear AI. Last updated on 9 Jul 2025.
Lantheus Financial Performance
Revenues and expenses
Lantheus Earnings Performance
Company profitability
Lantheus News
AllArticlesVideos
Why Is Lantheus Stock Trading Lower On Wednesday?
Benzinga·3 weeks ago
Lantheus Holdings, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - LNTH
Accesswire·3 months ago
Lantheus Holdings, Inc. (LNTH) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights
Accesswire·3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Lantheus stock?
Lantheus (LNTH) has a market cap of $3.6B as of August 07, 2025.
What is the P/E ratio for Lantheus stock?
The price to earnings (P/E) ratio for Lantheus (LNTH) stock is 13.75 as of August 07, 2025.
Does Lantheus stock pay dividends?
No, Lantheus (LNTH) stock does not pay dividends to its shareholders as of August 07, 2025.
When is the next Lantheus dividend payment date?
Lantheus (LNTH) stock does not pay dividends to its shareholders.
What is the beta indicator for Lantheus?
Lantheus (LNTH) does not currently have a Beta indicator.